R&D Pipeline

Phase:

Therapy:

16 compounds matching your criteria
Compound/indication Phase 1 Phase 2 Phase 3 Filed
NovoMix® 50 and 70

Type 1 and 2 diabetes
Activelle® low dose

Hormone replacement therapy
Liraglutide

Type 2 diabetes
Vagifem®

Hormone replacement therapy
rFXIII Congenital deficiency

Haemostatic agent
NN1250

Type 1 and 2 diabetes
NN5401

Type 1 and 2 diabetes
Liraglutide as anti-obesity agent

Obese, non-diabetic people
rFVIIa fast-acting analogue

Haemostatic agent
Once-weekly GLP-1 analogue (NN9535)

Type 2 diabetes
Long-acting growth hormone

Growth disorder
rFVIIa long-acting derivative

Haemostatic agent
rFVIIa for subcutaneous administration

Haemostatic agent
rFXIII Cardiac surgery

Haemostatic agent
Anti-IL20

Inflammation
Anti-C5aR

Inflammation
  •